KALA BIO Investor Relations Material
Latest events
Q1 2025
14 May, 2025
Q4 2024
31 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from KALA BIO Inc
Access all reports
KALA BIO Inc. (formerly Kala Pharmaceuticals Inc.) is a biopharmaceutical company focused on developing and commercializing innovative treatments for ocular diseases. The company leverages its proprietary AMPPLIFY drug delivery technology, which enhances the penetration of therapeutic agents into target tissues. KALA BIO’s product portfolio includes treatments for conditions such as dry eye disease, ocular inflammation, and other front-of-the-eye disorders. The company is headquartered in Arlington, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
KALA
Country
🇺🇸 United States